NewsRoom Articles - Page 34 of 207

MondayApr 22, 2024 10:30 am

Clene Inc. (NASDAQ: CLNN) Continues Development of Lead Drug Candidate CNM Au8(R) for Neurodegenerative Diseases including Parkinson’s Disease

CNM-Au8 is an oral suspension with demonstrated activity in restoring neuronal health and function by increasing energy production and utilization Treatment with CNM-Au8 investigated in clinical trials adjunctive to standard-of-care exhibits no known drug interactions, and aims to enhance function and survival Nearly 90,000 people are diagnosed with Parkinson's disease every year with no approved drug to slow or halt disease progression currently available The Parkinson's disease treatment market was valued at $4.61 billion in 2022 and is expected to reach $11.98 billion by 2030 In recognition of April as Parkinson’s Disease Awareness Month, IBN is highlighting Clene (NASDAQ: CLNN),…

MondayApr 22, 2024 10:00 am

CMS Completes New Rules Modifying Medicare Advantage Program

Earlier this month, the Centers for Medicare and Medicaid Services (CMS) published a regulation implementing changes in policy to Medicare Part C and Part D. The changes expand on policies under the Biden-Harris administration to promote healthy competition, strengthen guardrails and protections, and ensure Medicare Part D plans meet the needs of all who enroll. The changes in policy include restrictions on beneficiary data distribution, revisions on compensation rules for brokers and agents who hinder anticompetitive steering, and improvements to behavioral health access. We look at them in detail below. Limitations on beneficiary data distribution by third-party marketing organizations The…

FridayApr 19, 2024 10:00 am

Misinformation on TikTok Causing Many to Misdiagnose Themselves as Autistic

As the global youth population increases its use of social media, misinformation continues to be a danger to many. Joseph O’Brien, a manager at Inspira Health’s Behavioral Wellness Center, stated that social media had increased the dangers of self-diagnosis. Social media apps such as TikTok are already used to spread misinformation, particularly on developmental and mental-health conditions. Various posts include individuals sharing their self-diagnosis of conditions such as autism spectrum disorder despite mental-health professionals on the same TikTok platform highlighting the importance of getting diagnosed by a licensed medical provider. A recent study by the A.J. Drexel Autism Institute determined…

WednesdayApr 17, 2024 10:00 am

New Study Shows Social Isolation, Frailty Worsen Health Risks for Aging People

A recently published review has found that social vulnerability and frailty worsen as individuals age. When both are present, these conditions result in a considerably heightened decline in cognitive and physical function as well as mortality risk. So, what is frailty? Theoretically, frailty is defined as a state of heightened vulnerability resulting from declines associated with age that is clinically recognizable. These declines often compromise an individual’s ability to cope with acute stressors, with researchers noting that frailty is common among older people. While advancements in modern medicine have significantly improved life expectancy of humans beyond natural limits, frailty remains…

TuesdayApr 16, 2024 9:45 am

Astiva Health Inc. Committed to Creating Healthcare Model Focused on Collaboration Between Physician and Patient

Duke reports that physician-patient relationships can have profound positive and negative implications on clinical care” The dynamic between a physician and patient can be impacted by the ability to speak articulately, including the knowledge of a foreign language, and racial and cultural differences Astiva Health specializes in innovative health plans tailored to meet the unique requirements of its members Astiva Health has a network of providers that closely matches patients’ demographic background, interest, language and culture. This does not come by luck. Astiva has always been working on improving its provider network and physician-patient assignment, ensuring health plans align with client…

MondayApr 15, 2024 10:00 am

Study Identifies Three Distinct Subtypes of Multiple Sclerosis

Multiple sclerosis (MS) is a chronic illness that affects an individual’s central nervous system. The disease manifests differently in each individual and has varying trajectories, which makes it difficult to manage. It also has no cure. New research has identified three subtypes of the disease based on immune markers observed in participants’ blood. For the research, a team of investigators led by Professor Heinz Wiendl, a professor at the University of Münster, conducted a comprehensive analysis of the immunological properties of different blood samples collected from more than 300 early multiple sclerosis patients and a validation group made up of…

FridayApr 12, 2024 10:00 am

Study Finds Presurgery Immunotherapy Safe for Patients with Pancreatic Cancer

Pancreatic cancer is a challenging cancer to treat. Research shows that roughly 12% of individuals diagnosed with this particular cancer live beyond five years. Additionally, treatments such as chemotherapy, immunotherapy and targeted therapies are unsuccessful in treating pancreatic cancer. Prior research has determined that combined PD1-inhibitors and chemotherapy hasn’t brought any improvements in pancreatic cancer patients. PD1-inhibitors are an immunotherapy drug that assists the immune system in recognizing and eliminating cancer cells effectively. Now, new research suggests that individuals with pancreatic cancer can undergo immunotherapy prior to surgery, with scientists noting that this may improve long-term outcomes. The research was…

WednesdayApr 10, 2024 10:00 am

Hackers Exploit Bug in Magento to Access Payment Data on eCommerce Sites

A critical flaw in the open-source e-commerce platform Magento has allowed hackers to make backdoors into e-commerce websites and steal payment data. Computer software company Adobe Inc. describes the error, CVE-2024-2072, as the “improper neutralization of special elements” that could allow attackers to make arbitrary code executions without any user interaction. Adobe addressed the vulnerability on Feb. 13, 2024, as part of a batch of security updates while e-commerce security company Sansec announced that it had found a database layout template that was used to “inject malicious code” automatically. Hackers could then use this code to execute commands arbitrarily by…

WednesdayApr 10, 2024 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients AVERSA technology can be incorporated into any transdermal patch The company has a broad intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico and Australia Nutriband announced in March 2024 that it will submit a New Drug Application to the FDA seeking approval to market AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch In April 2024, the company announced it had received a contract manufacturing order from…

TuesdayApr 09, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug

Clinical trials of Clene’s lead candidate CNM-Au8(R) have shown notable success in crossing the blood-brain barrier and enhancing the brain's bioenergetic metabolites, essentially "reversing the clock" on what would be considered healthy aging CNM-Au8 has shown promise in clinical trials for both ALS and MS, including improvements in survival rates and clinical function Clene was recently featured in an interview of CEO Rob Etherington on ‘First in Human’ podcast In a significant advancement for the treatment of neurodegenerative diseases, Clene (NASDAQ: CLNN) has innovated CNM-Au8, an oral nanotherapeutic designed to revitalize the brain's mitochondrial function. The potential of this drug…